|
|
第57卷 第2期 2024-3
Necrotizing fasciitis resulted from foreign body ingestion and intestinal perforation in an incisional hernia: Report of a case |
| ......................... |
|
第57卷 第2期 2024-3
Application of artificial intelligence in endodontic microsurgery |
| ......................... |
|
第57卷 第2期 2024-3
A rare case of cerebral metastasis of malignant peripheral nerve sheath tumor in a patient with neurofibromatosis type 1 |
| ......................... |
|
第57卷 第2期 2024-3
Ethic in commenting and clinical surgery journal publication: Emerging issue in the era of social media—A story from “Beall” to “Jaime” and independent researcher |
| ......................... |
|
第57卷 第2期 2024-3
Ophidascaris robertsi, the new emerging human parasite and neurosurgery |
| ......................... |
|
第57卷 第2期 2024-3
Tetanus toxoid IgG, usefulness in clinical surgery, and diagnostic property limitation |
| ......................... |
|
第57卷 第2期 2024-3
Deaths among surgeons while on duty: An important issue in surgery and occupational medicine that should not be disregarded |
| ......................... |
|
第57卷 第2期 2024-3
ChatGPT and its use in clinical surgery: A comment on its pro and con |
| ......................... |
|
第57卷 第2期 2024-3
Isolated spinal neurocysticercosis and pseudotumor cerebri: Tropical problem to be noted |
| ......................... |
|
第57卷 第2期 2024-3
Management of massive hemothorax resulting from traumatic diaphragm rupture with kidney avulsion injury by combined anterior thoracoabdominal approaches |
| ......................... |
|
第57卷 第2期 2024-3
Laparoscopic partial splenectomy for sclerosing angiomatoid nodular transformation: A case report and literature review |
| ......................... |
|
第57卷 第2期 2024-3
Using three-dimensional versus two-dimensional laparoscopy in sleeve gastrectomy: A case matched comparison |
| ......................... |
|
第57卷 第2期 2024-3
Effectiveness of placing prophylactic mesh with the Sugarbaker technique via laparoscopic abdominoperineal resection for rectal cancer: 1-year results |
| ......................... |
|
第57卷 第2期 2024-3
Nylon cable ties–assisted delay primary closure of fasciotomy wound in patients of forearm compartment syndrome |
| ......................... |
|
第57卷 第2期 2024-3
Prefabricated venous fl ap, an advanced free venous fl ap for distant transfer: An experimental rat study |
| ......................... |
|
第57卷 第1期 2024-1
Isolated lower leg monoplegia due to traumatic intraparenchymal hemorrhage |
| ......................... |
|
第57卷 第1期 2024-1
Reflections on the association between cholecystectomy, cholelithiasis, and colorectal cancer |
| ......................... |
|
第57卷 第1期 2024-1
Molluscum contagiosum, false positive, and incidence: Concern in surgery |
| ......................... |
|
第57卷 第1期 2024-1
New form of COVID-19 vaccine: A new advanced technology for fighting the remained problem |
| ......................... |
|
第57卷 第1期 2024-1
COVID-19 vaccination, acute appendicitis, interrelationship, and jointed probability: A concern |
| ......................... |
|
 |
| 篇名 |
Metronomic Therapy for Metastatic Breast Cancer:a Preliminary Report |
| 作者 |
Fiona Tsui-Fen Cheng, Yenn-Hwei Chou, Yen-Kung Chen, Sheng-Chuan Hsi |
| 卷期/出版年月 |
40卷2期 (2007/4) |
| 頁次 |
75-80 |
| 摘要 |
Objectives: “Metronomic Therapy” was suggested by Kerbel et al. and is becoming
a newly applied regimen for cancer patients where low doses of chemotherapeutics at
a high frequency are used for long term treatment. This study aims to measure the
effectiveness of combining an initial traditional maximum tolerated dose regimen
with a metronomic agent as consolidating therapy.
Methods: From 2004 February to 2004 December, six female patients with an
average age of 49 years were enrolled in this pilot study. All the patients were
histologically identified as having metastatic breast cancer (MBC) and received oral
Tegafur/Uracil (UFURTM) 400mg per day as the consolidating agent until tumor
progression after they had initially received maximum tolerated dose chemotherapies
of DEC (Docetaxel 75 mg/m2, Epirubicin 75 mg/m2, Cyclophosphamide 500 mg/m2)
or DE (Docetaxel 75 mg/m2, Epirubicin 75 mg/m2) regimens for four to six
maximum cycles. Patients with Her2/neu positive were also treated by Trastuzumab
before initiating the Tagafur/Uracil treatment schedule. The diagnosis of response
was made according to CT, PET scans and Sonography every two months. We aimed
to see the prolongation in time to treatment progression (TTP).
Results: By April 2006, the median follow up time for the six patients was 19
months. One of the patients had progressed (lung metastasis) after 5 months and the
others were still receiving oral Tegafur/Uracil treatment. Two of the patients reached
partial response and other three patients remained in stable disease. The overall
response rate was 2/6 (33%)and clinical benefits including overall response and stable
disease was 5/6 (83%) with a median time to treatment progression of more than 16
months without severe hematological or non-hematological side effects.
Conclusion: Oral Tegafur/Uracil 400mg/day seemed to be effective as a metronomic
consolidating agent, and it would seem that this approach can significantly prolong
TTP when treating MBC and with very low toxicity. |
| 關鍵詞 |
metronomic, Tegafur/Uracil, UFUR, MBC |
| 分類 |
Original Article |
|
